🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
Joined March 2019
- Tweets127K
- Following138
- Followers42.8K
- Likes139K
Pinned Tweet
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
🧬 New in #JCOPO | Genomic landscape of 1,691 GEP-NENs
🔬 Annotated alterations: 34.1%
📊 NECs: 74.4% vs NETs: 28.5%
🎯 BRAF V600E in 14.8% of colorectal NECs
⚠️ NEC-like drivers in NETs predict worse OS (HR 3.67)
💡 Histology + NGS matter!
🔗 doi.org/10.1200/PO-26-00601
@OncoAlert
OncoAlert retweeted
Terrific work @tompowles1! Thank you @oncoalert for amplifying.
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
nejm.org/doi/full/10.1056/NE…
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
📣 Registration Now Open for #IKCSNA26
Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America, where a multidisciplinary community of leading experts from academia, clinical care, industry and advocacy come together to share ideas, explore emerging trends and shape the future of kidney cancer research and care.
🗓️ November 19–21, 2026
📍 Dallas, Texas
🏨 Renaissance Dallas Hotel
Register 👉 kidneycancer.org/event/2026-…
@KidneyCancer @LauraBukavinaMD @QingZhangLab @bergsa83 @mkbupathi @ADESAIONCMD @AmyLuckenbaugh @virajmaster @spsutkaMD @ChadTangMD @MVossMD @TiansterZhang @PavlosMsaouel @salvolarosa @GEVaughan1
OncoAlert retweeted
Dear Colleagues at #ESMO26
Inviting you to explore the @VJOncology Oncology content by tumor type. Each channel brings together congress coverage, trial breakdowns and expert insights, and videos covering more than one disease appear in every relevant channel, so you never miss an update. OncoAlert is a proud collaborator with VJ!
👉 Explore the coverage bit.ly/3WuLJRG
OncoAlert retweeted
44 out of 134 ‼️ That’s how often the world’s top prostate cancer experts agreed. The disagreements may matter even more.
sciencedirect.com/science/ar…
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
@Silke_Gillessen & @Aomlin
@Prof_Nick_James, @LVM_Walz, @AOmlin, @AttardLab, @bjartell, @LoebStacy, @Tilki_De, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @VedangMurthy, @neerajaiims, @Achard_Verane, @PBlanchardMD, @lisahorvath73, @BarbaraJereczek, @fontev1, @ChrisSweens1, @AarmstrongDuke, @CharlesRyanMD, @ProfKHerrmann, @KarimFizazi, @NealShore, @himishabeltran, @HeatherChengMD, @DrRanaMcKay, @AliciaMorgansMD, @declangmurphy, @DrSpratticus, @EvanYuMD, @NehaVapiwalaMD @drjefstathiou @BertrandTOMBAL
#APCCC26 brought together 144 international🌐 #ProstateCancer experts to tackle questions where high-level evidence is limited. Using a modified Delphi process, 133 panellists voted on 134 questions covering high-risk localised, locally advanced and biochemically recurrent disease, including PSA persistence, PSA recurrence and treatment side effects.
✅️ Consensus (≥75% agreement) was reached on 44 questions (32.8%), with strong consensus (≥90%) on seven.
👉 Areas without consensus highlight key priorities for future trials.
OncoAlert retweeted
Two active drugs. A closer look at what each contributes. 🎙️
In Episode 522, Anders Ullén joins the Uromigos to unpack an exploratory three-arm KEYNOTE-905 analysis in cisplatin-ineligible muscle-invasive bladder cancer, discussing pembrolizumab’s activity, the added contribution of EV, and the balance between efficacy and toxicity.
Swipe for the highlights, then hear the full discussion: bit.ly/4iv9Mro
#Uromigos #BladderCancer #ESMO26
OncoAlert retweeted
Watch our recent interview with @AndreaNecchi from #ESMO26 to hear final pathological and radiological outcomes, and initial EFS from the GDFather-NEO trial of nivolumab ± visugromab in #MIBC 📈🔬
🎥: ow.ly/TkLB5101sut
#Oncology @myESMO #TrialUpdate #ImmunoOnc #BladderCancer #BCSM
OncoAlert retweeted
📣GU update from #ESMO26!
Dr @DrIacovelli joined us at ESMO to share his views on #prostatecancer & #bladder cancer highlights from the meeting
Will updated OS results from #CAPItello-281, and phase 3 data from DASL-HiCaP; ANZUP1801 & VOLGA trials impact clinical practice?
Watch the video to find out!
🤝Programme endorsed by @WarOnCancer
📺Get the abstract details & see more updates from @myESMO in #gastriccancer, #crc, #pancreaticcancer, #HCC, #breastcancer & #NSCLC:
cor2ed.com/n-connect/program…
This educational programme is supported by COR2ED. For HCPs only.
#MedEd #OncTwitter #MedTwitter #PCSM
OncoAlert retweeted
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
OncoAlert retweeted
📌THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
👉🏻Register to receive it 👉 buff.ly/N5gYtAc 📩📩📩
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are @OncoAlert 🚨 For Colleagues, by Colleagues
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
OncoAlert would like to congratulate our faculty members on their nominations for the ASCO Elections! We are proud to see our OncoAlert🚨 faculty represented and wish all nominees the very best of luck in the election.
✅ Dr. Sumanta Pal ( @montypal ): Board of Directors Candidate @cityofhope
✅ Dr. Petros Grivas ( @PGrivasMDPhD ); Nominating Committee Candidate @fredhutch
✅ Dr. Rami Manochakian ( @RManochakian ) : Nominating Committee Candidate @MayoCancerCare
Voting is now open, and we encourage everyone to learn more about the candidates and participate in this important process.
🔗 Visit asco.org/election to learn more about the candidates and cast your vote.
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, , @Silke_Gillessen, @AOmlin, @brian_rini, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @DrMirallas, @MartinReck2 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @bensolomon1, @Latinamd, @ChristianRolfo @marinagarassino
OncoAlert retweeted
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
What an #EMSO26 it has been...impossible to oversee everything that has happened.
Luckily, you'll find everything you need to know in the @OncoAlert 🚨newsletter 👇
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
#ESMO26 by the numbers:
📣 101.7M potential reach 💬 6.1K posts, 988 participants, 34 countries 😊 45% positive, 6% negative
Science travels fastest when colleagues share it. Thank you all 🙏 Missed some of it?
Every key trial in one email 👉 buff.ly/N5gYtAc
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
OncoAlert retweeted
It is exciting to see our @aron_project on Sex-based differences in clinical outcomes of enfortumab vedotin and NECTIN-4 expression in urothelial cancer published on @NatureComms
Thanks to @TarekTahaMD @MatteoSantoniMD and all my Aron friends. @OncoAlert
OncoAlert retweeted
Dr. Razelle Kurzrock discusses the importance of early referral timing for ICI therapy in this new #JIPO Commentary and video interview. doi.org/10.36401/JIPO-26-X6
Interview: youtu.be/-HxHLDwQ2Rg
@Dr_R_Kurzrock
@jibranahmed1
@ANaingMD
@HajjarJoud
@SewantiLimaye
@weoncologists
@MDerbalaMD
@mirella_nardo
@ErulEnes
@ImeneHadji1
@RegmiSunil1
@OncologyNetwork
@OncoAlert
OncoAlert retweeted
Check out our Collaborators at COR2ED and this EXPERT insights from #ESMO26
GI oncologists Dr Lizzy Smyth, Dr Yelena Janjigian and Assoc. Prof. Gerald Prager join COR2ED at ESMO 2026 to provide their instant reactions on new data presented at the meeting. While Drs Smyth and Janjigian discuss gastric/GEJ cancer developments, Dr Prager will be focusing on colorectal and pancreatic cancer. @LizzySmyth1, @YJanjigianMD
cor2ed.com/esmo-2026/gastric…
OncoAlert retweeted
Join OncoAlert and our collaborators at @mirrorsmed for the 2026 Global Forum in GU Oncology
REGISTER HERE:
gu-global-forum.org/?utm_sou…
HERE is our friend Dr Philippe BARTHÉLÉMY 🇫🇷To Tell us more about this great forum!
December 2–5, 2026
Amsterdam, Netherlands
This is an excellent opportunity to learn how to translate the latest advances in oncology into your clinical practice. #Prosca26 #BLADDR25 #RENALC26
@BertrandTOMBAL, @Ric_Campi, @achoud72, @bkonety, @lisapic, @Achard_Verane, @MichvdHeijden, @roodvdb, @Zondervan_AUMC, @karolien_goffin
OncoAlert retweeted
🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
#Melanoma #OncoAlert
@DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
OncoAlert retweeted
🚨 Practice-changing in ES-SCLC? #ESMO26
Dr. Uğur Özkerim 🇹🇷 breaks down phase 3 DeLLphi-305 for #OAOnTheGo in Madrid. Presented by @sands_jacob and Simultaneously published in @NEJM.
Maintenance after 1L chemo-IO:
🔹 Tarlatamab + durvalumab vs durvalumab alone
🔹 Median OS: 21 vs 13 months
🔹 PFS also significantly improved
⚠️ Neurological toxicity needs close monitoring
🎥 👇 #OncoAlert #LungCancer #SCLC
Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers